Introduction

Cancer patients experience many concurrent symptoms that significantly compromise their emotional and functional status and their quality of life [1, 2]. As patients rarely present with a single symptom, there is a perceived need to shift the paradigm of symptom management research from trying to understand any one particular symptom in isolation to a broader focus on evaluating the relationship among multiple symptoms [1].

As a dynamic construct, the term symptom cluster (SC) has been defined as two or more interrelated symptoms that present together, independent of other SCs, and may possibly suggest a common etiology or underlying mechanism [3]. It is possible to identify SCs in both cancer and non-cancer patients [4]. In oncology, the investigation of SCs has been performed mostly on early-stage cancer [5, 6], specific primaries [7, 8], and specific metastatic sites [9, 10]. However, there is a paucity of such studies in advanced cancer patients (ACPs) who are currently...
neither receiving chemo- nor radiotherapy and have high symptom burden [11, 12].

Overall survival is an important endpoint for patients with advanced cancer. Recent studies have shown that adequate symptom management of ACPs offers better quality of life and improves prognosis [13]. In advanced cancer, individual symptom burden in different cancers has been associated with poor survival [14, 15]. Despite some studies suggesting that SCs are associated with poor survival in patients with specific primary cancers, the real impact of clusters on survival in cancer in general is still lacking [16]. A better knowledge of SC is crucial in the development of novel treatments in symptom management, which results in a significant benefit for patients with advanced cancer.

This study aimed to (1) identify the presence and composition of SCs in ACPs who were not receiving any type of anticancer treatment; (2) determine the patient characteristics associated with identified SCs; and (3) examine the strength of association of identified clusters with survival.

Methods

Study setting

The Hospital Santo António dos Capuchos (HSAC) is part of Central Lisbon Hospital Center, located in Lisbon, Portugal. The palliative care program at HSAC includes a consultation service that assesses urgent cases on a same-day basis, and a daily weekday palliative care outpatient clinic. Hospitalized patients with cancer were also referred to the palliative care service by other specialties. Consecutive referrals from among those admitted to HSAC and those referred by oncologists to the palliative care outpatient clinic were screened for study eligibility.

Subjects and eligibility

We conducted a prospective cohort study of consecutive ACPs who were referred to our palliative care program between October 2012 and May 2015 at the Department of Medical Oncology, HSAC. In this hospital, ACPs are commonly referred to Palliative Care Department for symptom management or for transition from the hospital to home or hospice care. These referrals may happen at different times in the disease trajectory, according to physician’s criteria. To meet this study, patients were: (1) aged 18 years or older; (2) evidence on diagnostic imaging of progressive advanced solid cancer with loco-regional or distant metastatic disease; (3) absence of anticancer therapy at time of referral; (4) no evidence of dementia or delirium on assessment with the Portuguese versions of the Short Portable Mental Status Questionnaire (SPMSQ) [17] and the Confusion Assessment Method (CAM) [18], respectively; and (5) ability to provide verbal or written answers to assessment measures and to sign written consent. Patients with hematological malignancies were excluded. All patients were enrolled and assessed at initial consultation with the palliative care service. This study was part of a longitudinal project that was approved by the hospital research ethics committee and informed consent of patients was obtained. This study reports on baseline cross-sectional data assessed at the initial consultation and survival.

Study measures and data collection

Baseline patient demographics were collected at initial palliative care consultation. Data on patients’ primary cancer location, metastatic sites and number, and type and date of last active cancer-specific treatment (chemotherapy, radiotherapy or other cancer-specific therapies such as tyrosine kinase inhibitors or endocrine therapies) were also gathered. Functional performance status (PS) was assessed with the Eastern Cooperative Oncology Group (ECOG) scale [19]. Cognitive status was evaluated with the Portuguese version of SPMSQ [17]. The validated Portuguese version of the CAM was used to screen for delirium [18]. Subjects meeting the study eligibility criteria had a comprehensive assessment of their symptom profile.

A total of 19 symptoms were assessed. All patients assessed by the palliative care team were requested to complete the revised version of the Edmonton Symptom Assessment Scale (ESAS) and 10 other symptoms using a Likert scale (1–5), as a routine component of the initial and subsequent consultations. The ESAS is a standardized 0–10 numerical rating tool (0 = not a problem, 10 = worst imaginable level of symptom) that is commonly used by palliative care teams to evaluate the intensity of nine symptoms: pain, dyspnea, lack of appetite, nausea, fatigue, drowsiness, anxiety, depression, and general well-being [20, 21]. It has been revised to facilitate its use (ESAS-r) [22], and this version of the instrument, used in this study, has been translated into Portuguese [23]. The ESAS-r was supplemented by questions about the following symptoms: dry mouth, vomiting, constipation, hiccups, sweating, weight loss, dysphagia, sleep disturbance, insomnia, and lack of memory. The intensity of these 10 symptoms was scored on a Likert scale: not at all = 1, a little = 2, moderate = 3, severe = 4, and extremely stressing = 5. Scores rated >2 on ESAS-r or >1 on Likert scale were deemed to be clinically significant and designated as measures of prevalence.

Our electronic records system was used to obtain laboratory data and to complete clinical data collected with patient forms.
Statistical analysis

Descriptive statistics were used to summarize baseline patient demographics, disease characteristics, and distributions of ESAS-r and Likert scores. The scores from both scales were normalized using z scores. Categorical data were analyzed using the Chi-Square test. A principal component analysis with varimax rotation was conducted on the standardized clinically significant intensity scores of the 19 symptoms to identify the SCs. The Kaiser-Meyer-Olkin measure was calculated to assess sampling adequacy (scores > 0.60 indicate adequate sample size for the analysis). A factor loading > 0.40 was considered as an inclusion criterion for each symptom. Derived factors were interpreted and discussed among the research team, and final factor structure included factors deemed to be clinically as well as statistically relevant. The internal consistency and reliability of the derived SC were assessed with the Cronbach’s alpha coefficient.

Survival analysis was based on the time elapsed between the date of study inclusion and the date of death or last follow-up. Kaplan–Meier estimator was applied to obtain group survival estimates and the log-rank test was used to compare survival between groups. Univariable and multivariable Cox regression models were fitted to the data considering time to death at 30 days. Among those variables that could influence the time to death at 30 days, a new variable (for each SC), characterizing each patient as having or not having a SC, was considered. Arbitrarily, the presence of at least 75% of the symptoms composing each SC was a set requirement for designating the presence of that given SC; otherwise, it was considered to be absent. The level of statistical significance for analyses was set at $\alpha = 0.05$. The statistical analysis was performed using SPSS version 21.0 (SPSS Inc., Chicago, IL).

Results

Of the 605 patients referred to the palliative care program, 157 were excluded due to cognitive deficit or delirium and 130 were on active cancer treatment (Fig. 1). Our analyses were conducted on the initial symptom assessments from 318 patients with advanced solid tumors. Among these, a further 17 were excluded: 14 restarted cancer treatment, 2 left the study, and 1 did not complete the questionnaire due to severe pain. Three hundred and one patients were included in the final analysis.

The baseline demographic details of our study sample are summarized in Table 1. The median age was 69 years (range: 37–94 years) and 172 (57.1%) were men. The most common primary cancer sites were gastrointestinal (27.6%), lung (17.6%), breast (15.6%), and genitourinary (13.0%). The majority of patients (67.4%) had two or more metastatic sites.

Table 1. Baseline patient characteristics.

| Clinical characteristics          | Number (%) of patients |
|----------------------------------|------------------------|
| Gender                           |                        |
| Male                             | 172 (57.1)             |
| Female                           | 129 (42.9)             |
| Age                              |                        |
| Median (years)                   | 69                     |
| Range                            | 37–94                  |
| ECOG                             |                        |
| 0                                | 3 (1.0)                |
| 1                                | 15 (5.0)               |
| 2                                | 88 (29.2)              |
| 3                                | 142 (47.2)             |
| 4                                | 53 (17.6)              |
| Hospital status                  |                        |
| Outpatient                       | 106 (35.2)             |
| Inpatient                        | 195 (64.8)             |
| Primary cancer site              |                        |
| Biliary tract                    | 12 (4.0)               |
| Breast                           | 47 (15.6)              |
| Gastrointestinal                 | 83 (27.6)              |
| Genitourinary                    | 39 (13.0)              |
| Gynecological                    | 13 (4.3)               |
| Hepatocarcinoma                  | 14 (4.7)               |
| Lung                             | 53 (17.6)              |
| Pancreas                         | 21 (7.0)               |
| Unknown                          | 9 (3.0)                |
| Other$^1$                        | 10 (3.3)               |
| Number of metastatic sites       |                        |
| 0                                | 13 (4.3)               |
| 1                                | 37 (12.3)              |
| >1                               | 251 (83.3)             |

$^1$This group includes central nervous system, head and neck, skin mesothelioma and sarcomas. ECOG, Eastern Cooperative Oncology Group.
more metastatic sites. Patients with no metastases included those with locally advanced disease and no disease else-
where. A total of 65% of patients had a PS of 3 or 4.

In Table 2, symptom prevalence and severity are des-
dcribed. The median number of symptoms was 9 (0–18) and the most common symptoms were tiredness, pain, somnolence, dry mouth, and weight loss, ranging in preva-
ence from 80.7% to 100%.

Table 3 shows the three identified SCs that accounted for
39.7% of the total variance in symptom scores. The neu-
ro-psycho-metabolic (NPM) cluster included tiredness,
lack of appetite, dyspnea, anxiety, and lack of well-being;
the gastrointestinal (GI) cluster included nausea, vomiting,
constipation, dry mouth, and hiccups; and sleep impair-
ment (SI) cluster included insomnia and sleep distur-
bance. The NPM, GI, and SI clusters were present
in 131 (43.5%), 51 (16.9%), and 139 patients (46.2%),
respectively. One hundred and five patients (34.9%) had
one SC, 79 (26.2%) had two, and 18 (6.3%) had all
SCs. The NPM, GI, and SI clusters demonstrated internal
consistency and validity with good Cronbach’s alpha coef-
ficient values of 0.74, 0.59, and 0.86, respectively. The
same cluster analysis to the subgroup of patients with GI
cancers (n = 133) was performed, and the same three
clusters were identified (Cronbach’s alpha of 0.76, 0.67
and 0.85, respectively), although this subgroup differed
by having more men (65% vs. 57%), better PS (43% vs.
35% with ECOG 0–2), and more with an outpatient
designation (42% vs. 35%) when compared to the general
study population, respectively.

The frequency of SCs among different primary tumors
was analyzed in cancers with a study sample prevalence of
1%: lung, gastrointestinal, breast, and genitourinary
tumors. The cluster NPM was present in 57% of lung
and breast cancers, and in 37% and 31% of GI and GU
cancers, respectively. The GI cluster was rarely present in
lung cancer (4%) and less frequent in breast and GU
cancers (13%) than reported for all cancers. The highest
NPM frequency was observed in GI cancers (27%). The
frequency of the SI cluster was very similar in all groups;
its presence ranged between 41% and 49% of the cases.

We performed an exploratory analysis to assess the
factors related to the presence of one SC in particular.
This analysis included tumors with at least 45 patients:
lung, breast, and gastrointestinal cancers. The cluster NPM
was more common (76% vs. 24%, P = 0.028) in patients
with PS 3 and 4 versus 0–2, and in those hospitalized
versus not hospitalized (75% vs. 25%, P = 0.031). Patients
with gastrointestinal cancer had the NPM cluster and GI
cluster less frequently, with presence versus absence of
37% versus 63% and 27% versus 73%, respectively
(P < 0.001).

Finally, the strength of association of the SCs with
survival was analyzed. The median survival of the whole
cohort was 37 (95% CI: 28–46) days. A statistically sig-
nificant reduction in survival was observed for patients
with the NPM cluster compared to those without the
cluster (58 days vs. 23 days, P < 0.001, see Fig. 2A). No
difference in survival was observed for the presence of
the GI and SI clusters, nor the cancer specific-treatment
received (P = 0.788) before inclusion. The number of
SCs present in any given patient was related to survival:
patients with two or more clusters lived a median of 21
(95% CI: 17–25) days, compared with a median of 45
(95% CI: 32–58) days for those with one or zero clusters
(P = 0.005) (Fig. 2B).

In the univariable Cox regression analysis, variables
potentially influencing time to death at 30 days, with a
P < 0.25, were selected for the multivariable model: age,
PS, hospital status, and NPM and SI clusters. Remarkably,
the variables sex, site of metastases, GI cluster, and can-
cer-specific treatment were not significantly associated with
time to death. In the multivariable model, younger age
(HR: 0.98; 95% CI: 0.97–0.99; P = 0.008), hospitalization
at inclusion (HR: 2.27; 95% CI: 1.47–3.51; P < 0.001),
poorer PS (HR: 1.90, 95% CI: 1.24–2.89; P = 0.003), and
NPM cluster presence (HR: 1.64; 95% CI: 1.17–2.31;
P = 0.005), were independently associated with worse
survival at 30 days.

Table 2. Symptom clusters composition and relative frequencies.

| Symptom       | Symptom prevalence (%) | Mean score (SD) | Median score (P25–P75) |
|---------------|------------------------|-----------------|------------------------|
| ESAS          |                        |                 |                        |
| Pain          | 251 (83.3)             | 5.8 (2.2)       | 6 (4–8)                |
| Tiredness     | 301 (100)              | 6.2 (2.9)       | 7 (4–9)                |
| Somnolence    | 249 (82.7)             | 4.6 (3.2)       | 5 (2–7)                |
| Nausea        | 91 (30.2)              | 5.9 (2.2)       | 7 (4–8)                |
| Lack of appetite | 225 (74.8)           | 7.0 (2.2)       | 7 (5–9)                |
| Dyspnea       | 91 (30.2)              | 7.0 (2.3)       | 7 (5–8)                |
| Depression    | 225 (74.8)             | 7.0 (2.1)       | 7 (5–8)                |
| Anxiety       | 178 (59.1)             | 6.3 (2.2)       | 7 (4–8)                |
| Lack of well-being | 234 (77.8)         | 6.3 (2.0)       | 7 (5–8)                |
| Likert scale  |                        |                 |                        |
| Vomiting      | 75 (24.9)              | 2.8 (0.9)       | 3 (2–3)                |
| Constipation  | 160 (53.2)             | 3.2 (1.0)       | 3 (2–4)                |
| Weight loss   | 243 (80.7)             | 3.5 (0.9)       | 4 (3–4)                |
| Dysphagia     | 89 (29.6)              | 3.1 (1.1)       | 3 (2–4)                |
| Dry mouth     | 249 (82.7)             | 3.4 (1.0)       | 4 (2–4)                |
| Sweating      | 63 (20.9)              | 2.8 (1.0)       | 3 (2–3)                |
| Hiccups       | 63 (20.9)              | 2.8 (1.0)       | 3 (2–3)                |
| Insomnia      | 173 (57.5)             | 3.1 (0.9)       | 3 (3–4)                |
| Sleep disturb | 159 (52.8)             | 3.2 (0.9)       | 3 (3–4)                |
| Lack of memory| 115 (38.2)             | 2.7 (0.9)       | 2 (2–3)                |

Symptom is considered prevalent if ESAS score > 2 or Likert score > 1. ESAS, Edmonton Symptom Assessment Scale; SD, Standard deviation.
Discussion

The study of SCs may be particularly relevant for patients with advanced cancer because they frequently report multiple, concurrent symptoms that are difficult to control [24]. As in previous reports, people with advanced cancers are polysymptomatic, a common feature across all primary sites [25, 26].

We investigated SCs in a sample of patients with advanced cancer, different solid tumors, and not receiving any type of disease-modifying, anti-cancer treatment.

Among all of the 19 symptoms that were assessed, six (pain, somnolence, weight loss, dysphagia, sweating, and lack of memory) were not included in any of the clusters identified in our study. Although these exclusions were not particularly surprising for most of these symptoms, we would have expected pain—to be identified as part of a cluster or associated with other clusters identified, as reported in previous studies [11, 27]. The lack of association of pain with depression, anxiety, or lack of well-being was also noted in a recently published Portuguese study of cancer pain [28]; the authors questioned the

Table 3. Frequency of the different symptom clusters identified.

| Symptoms                        | N (% of patients) | Factor loading score | % of variance | Cronbach’s α |
|---------------------------------|-------------------|----------------------|---------------|--------------|
| Neuro-psycho-metabolic cluster  | 131 (43.5)        |                      | 17.31         | 0.736        |
| Tiredness                      | 0.718             |                      |               |              |
| Lack of appetite                | 0.498             |                      |               |              |
| Dyspnea                        | 0.538             |                      |               |              |
| Depression                     | 0.684             |                      |               |              |
| Anxiety                        | 0.618             |                      |               |              |
| Lack of well-being             | 0.703             |                      |               |              |
| Gastro-intestinal cluster      | 51 (16.9)         |                      | 12.39         | 0.591        |
| Nausea                         | 0.600             |                      |               |              |
| Vomiting                       | 0.758             |                      |               |              |
| Constipation                   | 0.522             |                      |               |              |
| Dry mouth                      | 0.410             |                      |               |              |
| Hiccups                        | 0.545             |                      |               |              |
| Sleep impairment cluster       | 139 (46.2)        |                      | 9.99          | 0.864        |
| Insomnia                       | 0.869             |                      |               |              |
| Sleep disturbance              | 0.828             |                      |               |              |

Figure 2. Kaplan–Meier survival estimates according to the presence of symptom cluster. (A) Neuro-psycho-metabolic (NPM) cluster. (B) Number of symptom clusters present.
Symptom Clusters and Survival

Possibility of cultural explanations or cultural misinterpretation in the context of some assessment tools. Alternatively, our finding may suggest that the presumed strong relationship between those pain and psychological distress variables may, as suggested in previous studies, be somewhat exaggerated [11, 29]. Meanwhile, it is possible that somnolence and weight loss may be viewed and rated with less and account for their failure to be included in a cluster, albeit that the characteristics of this heterogeneous population limit definitive conclusions on this regard.

The most common cluster, SI was present in almost half (46%) of our patients. The symptoms of insomnia and sleep disturbance that comprise this cluster are among some of the most frequent symptoms experienced by patients with cancer [30]. Despite the paucity of studies on sleep disturbance in advanced cancer patients, a prospective study that assessed the prevalence of sleep disorder in an acute palliative care unit reported that 30% of patients slept <5 h [31]. These data together with our findings support the need to incorporate attention to sleep disturbance into routine practice in supportive care.

The second most common cluster in our study, NPM (44%), has also been found in several other studies, in which its prevalence was either partially or totally represented [11, 12, 24, 32–34]. Among four of these studies, which were conducted in patients with advanced cancer, one of them identified a cluster with 4 of the NPM symptoms that were identified in our current study; [33] another identified 2 of our study’s NPM symptom cluster[34]; the other two studies grouped the symptoms of depression and anxiety with sleep problems to comprise a distinct symptom cluster in their studies [11, 12]. The combination anorexia-tiredness is also described as an anorexia-cachexia cluster in other studies [11, 12]. This anorexia-tiredness syndromal combination may be associated with among other factors, cytokine release, such as C-RP, interleukin-6, and tumor necrosis factor-alpha [34, 35]. Meanwhile, given previously published data, the association of anorexia-cachexia with anxiety and depression was not a surprise. In a large prevalence study of advanced cancer patients with different cancers, the factors poor PS, anorexia, and anxiety were independent predictors of depression, fatigue, and pain in multivariate analysis [35]. However, the exact mechanism for this association is unknown and whether the psychological component is a cause or consequence of physical deterioration is not completely known.

Interestingly, among the published studies in patients with advanced cancer that assessed sleep-related symptoms, those symptoms comprising the SI cluster in our study were integrated in NPM cluster [5, 12]. Furthermore, the association between sleep issues and NPM was suggested in another study performed in advanced cancer patients admitted to a palliative care unit for pain management; awaking early, anxiety, and depression were among the factors significantly associated with less hours slept [31]. The GI cluster was present in 17% of our patients. While this cluster had the Cronbach’s alpha (0.59), the presence of this cluster in the subgroup of patients with GI malignancies was also statistically significant.

Furthermore, the GI cluster has already been reported in several studies among different populations worldwide, including the English, Chinese, and Filipino validation studies of the symptom assessment instrument from MD Anderson Cancer Center (MDASI) [36–38]. In these studies, the GI cluster was observed in higher prevalence (ranging from 23 to 28%) than in our patients [11, 12, 24, 27]. To the best of our knowledge, we are unaware of specific symptom clusters research on patients with GI-advanced cancers; however, in many studies, GI malignancies are the most common primaries included [12, 24, 27].

It is noteworthy that the symptom constipation clustered together with the other gastrointestinal symptoms of the GI cluster. This finding suggests that “upper” and “lower” gastrointestinal symptoms may be inter-related, which may have therapeutic implications. Even if they do not share the exact same pathophysiology, effective therapy may relieve one symptom and either relieve or prevent another, for example relief of constipation, thus preventing nausea caused by intestinal stasis or occlusion [11, 26]. In most of the studies reporting a GI cluster, mean scores for nausea and vomiting were significantly higher in advanced cancer patients receiving chemotherapy [11, 39, 40]. Furthermore, in the study where chemotherapy was not a factor influencing the GI cluster, there was a significant proportion of patients with PS 0 or 1, and the majority of them had early-stage disease [36]. The exclusion of patients on cancer-specific treatments as a criterion to be eligible for participation in our study may possibly explain the lower prevalence of the GI cluster that we observed.

Among the most frequent cancers, we found that PS and hospital status were associated with specific SC. The NPM cluster occurred predominantly in hospitalized patients with poorer PS and with breast or lung cancer. These findings suggest that the NPM cluster may be associated with deterioration in physical and psychological functioning in patients with advanced cancer, especially in those with a thoracic neoplasm. Indeed, the association of this cluster with worse survival supports this finding. The GI cluster was more commonly observed in gastrointestinal cancers, which is unsurprising and in line with published data, showing a clear relationship between GI symptoms and the anatomic site of primary cancer [11, 12]. We must acknowledge that many other factors with
the potential to influence the clustering of symptoms have been identified in other studies, including age and gender; and other factors that were not formally evaluated in our study, such as psychological distress or fluid accumulation [24, 41].

In our study, short-term survival was independently associated with younger age, poorer PS, and hospitalization. Contrary to what one might expect, younger patients had worse survival. These patients were more tired ($P < 0.001$) and depressed ($P = 0.018$) (data not shown), although no differences in NPM and age were identified. We admit that differences in primary site distribution may help to explain these findings, as liver and intrahepatic bile duct, breast, and upper GI malignancies, which affect more people younger than 70 years old, were more prevalent in our cohort than in general population [42]. In one study by Walsh et al. [25], age was also identified as an independent predictor of morbidity, regardless of primary tumor location. Furthermore, the inclusion of age and PS in future studies addressing symptom management is suggested.

The presence of more than one cluster, as well as the NPM cluster had a negative association with survival. In fact, the association of symptom burden with survival has already been reported in a number of studies [41, 43, 44]. However, very few studies investigated the prognostic importance of SCs in advanced cancer patients [12, 27]. Our results support the clinical relevance of examining survival as an outcome of symptom cluster research. The prognostic value of SCs could be used to develop survival models, and thus provide useful information to guide both oncologists and palliative care experts in their clinical decisions.

The findings of this study are somewhat preliminary given the relative paucity of reported studies on SCs in advanced cancer and the lack of methodological consistency among reported studies. Indeed, different methods may identify different sets of clusters, and results may vary depending on the statistical analysis technique used [32, 45]. We used principal component analysis, as it is one of the most common methods used in SC research. Because the analysis is based on the symptoms and scaling used in assessment tools, we admit that our 19-item questionnaire may produce results different from those originating with a smaller or larger item symptom inventory, as already noted by different authors [32].

Certain characteristics of our study sample need to be acknowledged. Given the differences in pathophysiology, behavior, and clinical outcomes between hematological and solid tumors, we excluded patients with hematological malignancies in order to minimize potential differences in the study population. Furthermore, almost two-thirds of the patients were hospitalized at time of inclusion, likely reflecting various complications associated with advanced cancer. However, all of them were admitted at the HSAC site, excluding those admitted at other hospitals from under the broader CHLC organization. This could lead to a selection bias of patients included in the study. Furthermore, CHLC is a recognized cancer center for GI malignancies, especially biliary tract, hepatic and pancreatic cancers, as well as thoracic malignancies. We admit that the proportion of different primary cancers seen in this study, such as the high proportion of liver/intrahepatic bile duct and pancreatic tumors, is not representative of the cancer population at large or comparable to other series, and thus it may have influenced the results. Despite these limitations, other investigators, in similar settings, have also described similar SCs. Furthermore, we have identified the same clusters in a more homogeneous group of patients with GI tumors, which supports the validity of these associations of symptoms. Nonetheless, these findings will need to be replicated in further studies to draw conclusions [11, 12, 32]. Future studies stratifying patients according to clusters and see its impact on survival should be conducted to develop treatment strategies with a positive impact on outcomes. Finally, the prospective evaluation of SC over time has been rarely performed. To answer the question whether the prevalence and intensity of the clusters change over time with disease evolution, this study is part of a longitudinal project with repeated measures over time.

These data have important implications for medical practice and clinical research. SCs may have prognostic value. The importance of regular assessment of symptom burden and SCs in clinical practice should not be underestimated. As recommended by other authors, the identification of clinically meaningful subgroups of patients that are in need of strategically targeted therapeutic intervention supports the need both for more rigorous exploratory studies and the inclusion of cluster assessment data in future treatment evaluation strategies.

Conclusions

We identified three clinically meaningful SCs in patients with advanced cancer. The NPM cluster, the presence of two or more clusters, as well as age, performance status and hospitalization, had prognostic value. Further studies are needed to better characterize these clusters, their evolution over time, and evaluate potential therapeutic interventions.

Acknowledgment

The authors thank to Dr. Ana Trindade, Dr. António Mesquita, Dr. Frederico Filipe, Dr. Hugo Ribeiro and
Dr. Sónia Duarte Oliveira, for their contribution on data collection; to Flávia Pinto and Hugo Sousa for logistical assistance.

**Conflicts of Interest**

None declared.

**References**

1. Miaskowski, C., M. Dodd, and K. Lee. 2004. Symptom clusters: the new frontier in symptom management research. J. Nat. Cancer. Inst. Monogr. 32:17–21.
2. Portenoy, R. K., H. T. Thaler, A. B. Kornblith, J. M. Lepore, H. Friedlander-Klar, N. Coyle, et al. 1994. Symptom prevalence, characteristics and distress in a cancer population. Qual. Life Res. 3:183–189.
3. Dodd, M., S. Janson, N. Facione, et al. 2001. Advancing the science of symptom management. J. Adv. Nurs. 33:668–676.
4. Stiel, S., D. M. Matthies, D. Seuss, D. Walsh, G. Lindenau, and C. Ostgathe. 2014. Symptoms and problem clusters in cancer and non-cancer patients in specialized palliative care—is there a difference? J. Pain Symptom Manage. 48:26–35.
5. Chen, M. L., and C. C. Lin. 2007. Cancer symptom clusters: a validation study. J. Pain Symptom Manage. 34:590–599.
6. Molassiotis, A., Y. Wengstrom, and N. Kearney. 2010. Symptom cluster patterns during the first year after diagnosis with cancer. J. Pain Symptom Manage. 39:847–858.
7. Gift, A. G., A. Jablonski, M. Stommel, and C. W. Given. 2004. Symptom clusters in elderly patients with lung cancer. Oncol. Nurs. Forum 31:202–212.
8. Bender, C. M., F. S. Ergyn, M. Q. Rosenzweig, S. M. Cohen, and S. M. Sereika. 2005. Symptom clusters in breast cancer across 3 phases of the disease. Cancer Nurs. 28:219–225.
9. Chow, E., G. Fan, S. Hadi, J. Wong, A. Kirou-Mauro, and L. Filipczak. 2008. Symptom clusters in cancer patients with brain metastases. Clin. Oncol. (R. Coll. Radiol.) 20:76–82.
10. Chow, E., G. Fan, S. Hadi, and L. Filipczak. 2007. Symptom clusters in cancer patients with bone metastases. Support. Care Cancer 15:1035–1043.
11. Walsh, D., and L. Rybicki. 2006. Symptom clustering in advanced cancer. Support. Care Cancer 14:831–836.
12. Jimenez, A., R. Madero, A. Alonso, et al. 2011. Symptom clusters in advanced cancer. J. Pain Symptom Manage. 42:24–31.
13. Temel, J. S., J. A. Greer, A. Muzikansky, et al. 2010. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 363:733–742.
14. Dev, R., D. Hui, E. Del Fabbro, et al. 2014. Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer. Cancer 120:1586–1593.
15. Wang, X. S., Q. Shi, C. Lu, et al. 2010. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer 116:137–145.
16. Gough, N. J., C. Smith, J. R. Ross, J. Riley, and I. Judson. 2011. Symptom burden, survival and palliative care in advanced soft tissue sarcoma. Sarcoma 2011:325189.
17. García, C.. 1984. A doença de Alzheimer. Problemas de diagnóstico clínico (Alzheimer’s disease. Difficulties of clinical diagnosis): Ph. D. Thesis, Universidade de Lisboa.
18. Sampaio, F. M. C., and C. A. D. C. Sequeira. 2013. Translation and validation of the confusion assessment method for the portuguese population. Revista de Enfermagem Referência 9:125–134.
19. Oken, M. M., R. H. Creech, D. C. Tormey, et al. 1982. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:649–655.
20. Bruera, E., N. Kuehn, M. J. Miller, P. Selimser, and K. Macmillan. 1991. The edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J. Palliat. Care 7:6–9.
21. Cheung, V. T., S. S. Hwang, and M. Feuerman. 2000. Validation of the edmonton symptom assessment scale. Cancer 88:2164–2171.
22. Watanabe, S. M., C. L. Nekolaichuk, and C. Beaumont. 2012. The edmonton symptom assessment system, a proposed tool for distress screening in cancer patients: development and refinement. Psychooncology 21:977–985.
23. Monteiro, D. D. R., M. D. A. Almeida, and M. H. L. Kruse. 2013. Translation and cross-cultural adaptation of the edmonton symptom assessment system for use in palliative Care. Revista Gaúcha de Enfermagem 34: 163–171.
24. Cheung, W. Y., L. W. Le, L. Gagliese, and C. Zimmermann. 2011. Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. Support. Care Cancer 19:417–423.
25. Walsh, D., S. Donnelly, and L. Rybicki. 2000. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1000 patients. Support. Care Cancer 8:175–179.
26. Komurcu, S., K. A. Nelson, D. Walsh, S. M. Donnelly, J. Homsi, and O. Abdullah. 2000. Common symptoms in advanced cancer. Semin. Oncol. 27:24–33.
27. Aktaş, A., D. Walsh, and L. Rybicki. 2012. Symptom clusters and prognosis in advanced cancer. Support Care Cancer 20:2837–2843.
28. Pina, P., E. Sabri, and P. G. Lawlor. 2015. Characteristics and associations of pain intensity in patients referred to a specialist cancer pain clinic. Pain Res. Manag. 20:249–254.
29. Fleishman, S. B. 2004. Treatment of symptom clusters: pain, depression, and fatigue. J. Nat. Cancer Inst. Monogr. 32:119–123.
30. Roscoe, J. A., M. E. Kaufman, S. E. Matteson-Rusby, et al. 2007. Cancer-related fatigue and sleep disorders. Oncologist 12(Suppl 1):35–42.
31. Mercadante, S., D. Girelli, and A. Casuccio. 2004. Sleep disorders in advanced cancer patients: prevalence and factors associated. Support. Care Cancer 12:355–359.
32. Fan, G., L. Filipczak, and E. Chow. 2007. Symptom clusters in cancer patients: a review of the literature. Current Oncol. 14:173–179.
33. Cheung, W. Y., L. W. Le, and C. Zimmermann. 2009. Symptom clusters in patients with advanced cancers. Support. Care Cancer 17:1223–1230.
34. Laird, B. J., A. C. Scott, L. A. Colvin, et al. 2011. Pain, depression, and fatigue as a symptom cluster in advanced cancer. J. Pain Symptom Manage. 42:1–11.
35. Hauser, K., L. Rybicki, and D. Walsh. 2006. Do pain, depression and fatigue cluster in advanced cancer? ASCO Annual Meeting Proceedings, 8522
36. Okuyama, T., X. S. Wang, T. Akechi, et al. 2003. Japanese version of the M. D. Anderson symptom inventory: a validation study. J. Pain Symptom Manage. 26:1093–1104.
37. Wang, X. S., Y. Wang, H. Guo, T. R. Mendoza, X. S. Hao, and C. S. Cleeland. 2004. Chinese version of the M. D. Anderson symptom inventory: validation and application of symptom measurement in cancer patients. Cancer 101:1890–1901.
38. Wang, X. S., A. V. Laudico, H. Guo, et al. 2006. Filipino version of the M. D. Anderson symptom inventory: validation and multisymptom measurement in cancer patients. J. Pain Symptom Manage. 31:542–552.
39. Chen, M. L., and H. C. Tseng. 2006. Symptom clusters in cancer patients. Support. Care Cancer 14:825–830.
40. Sarna, L., and M. L. Brecht. 1997. Dimensions of symptom distress in women with advanced lung cancer: a factor analysis. Heart Lung 26:23–30.
41. Tsai, J. S., C. H. Wu, T. Y. Chiu, and C. Y. Chen. 2010. Significance of symptom clustering in palliative care of advanced cancer patients. J. Pain Symptom Manage. 39:655–662.
42. Siegel, R., J. Ma, Z. Zou, and A. Jemal. 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64:9–29.
43. Palmer, J. L., and M. J. Fisch. 2005. Association between symptom distress and survival in outpatients seen in a palliative care cancer center. J. Pain Symptom Manage. 29:565–571.
44. Cheung, W. Y., N. Barmala, S. Zarinehbaf, G. Rodin, L. W. Le, and C. Zimmermann. 2009. The association of physical and psychological symptom burden with time to death among palliative cancer outpatients. J. Pain Symptom Manage. 37:297–304.
45. Kirkova, J., and D. Walsh. 2007. Cancer symptom clusters—a dynamic construct. Support. Care Cancer 15:1011–1013.